MicuRx(SH:688373) Zheng Quan Zhi Xing·2025-07-25 16:25Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. is set to list 159,444,366 restricted shares for trading on August 5, 2025, following its initial public offering (IPO) [1][3][6] Group 1: Listing Details - The total number of shares for this listing is 159,444,366, which are part of the restricted shares from the company's IPO [1][6] - The shares will be available for trading starting on August 5, 2025 [1][6] - The company received approval from the China Securities Regulatory Commission for the public offering of 13 million shares, which were listed on August 5, 2022 [1][3] Group 2: Shareholder Information - The restricted shares involve five shareholders: MicuRx(HK) Limited, Best Idea International Limited, JSR Limited, GP TMT Holdings Limited, and Xinyi Youmaikos Financial Consulting Center (Limited Partnership) [3][6] - The restricted period for these shares is 36 months from the date of the company's stock listing [3][4] Group 3: Changes in Share Capital - Following the implementation of the 2023 restricted stock incentive plan, the company's total share capital increased from 655,210,084 shares to 655,605,491 shares [2][3] - The increase in share capital is attributed to the vesting of restricted stocks under the incentive plan [2][3] Group 4: Shareholder Commitments - Shareholders have committed not to transfer or propose the repurchase of their shares during the 36-month lock-up period [4][5] - After the lock-up period, any share reduction must comply with relevant laws and regulations, ensuring that the selling price does not fall below the IPO price adjusted for any corporate actions [4][5] Group 5: Verification by Intermediaries - The sponsoring institution has verified that the application for the listing of restricted shares complies with legal requirements and that shareholders have adhered to their commitments [6]